412268-99-6 Usage
Description
3-(3-Phenylsulfamoylphenyl)acrylic acid methyl ester is a chemical compound with the molecular formula C15H15NO4S. It is a methyl ester derivative of 3-(3-phenylsulfamoylphenyl)acrylic acid, which contains a sulfonamide functional group. 3-(3-Phenylsulfamoylphenyl)acrylic acid methyl ester is known for its potential as a building block in the synthesis of various pharmaceuticals and bioactive molecules due to its unique structure and functional groups.
Uses
Used in Organic Chemistry Research:
3-(3-Phenylsulfamoylphenyl)acrylic acid methyl ester is used as a research compound in organic chemistry for its potential as a building block in the synthesis of various pharmaceuticals and bioactive molecules. Its unique structure and functional groups make it a versatile starting material for the development of new drugs or materials with specific properties.
Used in Pharmaceutical Development:
In the Pharmaceutical Industry, 3-(3-Phenylsulfamoylphenyl)acrylic acid methyl ester is used as a key intermediate in the synthesis of new drugs. Its sulfonamide functional group and other structural features contribute to the development of molecules with specific biological and pharmacological activities, making it an interesting compound for further investigation and development.
Used in Bioactive Molecule Synthesis:
3-(3-Phenylsulfamoylphenyl)acrylic acid methyl ester is utilized as a precursor in the synthesis of bioactive molecules. Its potential biological and pharmacological activities make it a valuable compound for creating molecules with therapeutic or diagnostic applications, further expanding its use in the life sciences and medicine.
Check Digit Verification of cas no
The CAS Registry Mumber 412268-99-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,1,2,2,6 and 8 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 412268-99:
(8*4)+(7*1)+(6*2)+(5*2)+(4*6)+(3*8)+(2*9)+(1*9)=136
136 % 10 = 6
So 412268-99-6 is a valid CAS Registry Number.
412268-99-6Relevant articles and documents
COMPOUNDS AND METHODS FOR TREATING CANCER
-
Paragraph 0190; 0233; 0236-0237, (2020/12/19)
Substituted cinnamamide compounds and analogs, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or ameliorate cancer are provided.
SOLID STATE FORMS OF (2E)-N-HYDROXY-3-[3-(PHENYLSULFAMOYL)PHENYL]PROP-2-ENAMIDE AND PROCESS FOR PREPARATION THEREOF
-
Page/Page column 15, (2018/03/06)
The Present invention relates to solid state forms of (2E)-N-hydroxy-3-[3-(N-phenyl sulfamoyl)phenyl]prop-2-enamide represented by the following structural formula-1 and process for the preparation thereof.
Novel sulfonamide derivatives as inhibitors of histone deacetylase
Finn, Paul W.,Bandara, Morwena,Butcher, Chris,Finn, Angela,Hollinshead, Ruth,Khan, Nagma,Law, Norman,Murthy, Sreenivasa,Romero, Rosario,Watkins, Clare,Andrianov, Victor,Bokaldere, Rasma M.,Dikovska, Klara,Gailite, Vija,Loza, Einars,Piskunova, Irina,Starchenkov, Igor,Vorona, Maxim,Kalvinsh, Ivars
, p. 1630 - 1657 (2007/10/03)
Inhibition of the enzyme histone deacetylase (HDAC) is emerging as a novel approach to the treatment of cancer. A series of novel sulfonamide derivatives were synthesized and evaluated for their ability to inhibit human HDAC. Compounds were identified which are potent enzyme inhibitors, with IC 50 values in the low nanomolar range against enzyme obtained from HeLa cell extracts, and with antiproliferative effects in cell culture. Extensive characterization of the structure - activity relationships of this series identified key requirements for activity. These include the direction of the sulfonamide bond and substitution patterns on the central phenyl ring. The alkyl spacer between the aromatic head group and the sulfonamide functionality also influenced the HDAC inhibitory activity. One of these compounds, m11.1, also designated PXD101, has entered clinical trials for solid tumors and haematological malignancies.
